Table 3 Predictors of Beliefs in Medicines Questionnaire (BMQ) scale responses a
Slope (SE) | p-value | |
|---|---|---|
Predictors of Specific Necessity - DFO | ||
Monotherapy vs. combination therapy | 2.39 (0.75) | 0.002 |
Regularly transfused | 2.84 (1.02) | 0.006 |
Number of complications | 0.39 (0.18) | 0.031 |
Predictors of Specific Concerns - DFO | ||
Age group | 0.04 | |
Young adult vs. child | −2.45 (0.95) | |
Adult vs. child | −1.87 (0.99) | |
Race | <0.001 | |
Asian vs. white | 1.91 (0.66) | |
Other vs. white | −5.25 (2.15) | |
Country | 0.004 | |
Canada vs. US | 1.89 (0.93) | |
UK vs. US | 2.80 (1.03) | |
Predictors of Specific Necessity – Oral Chelator | ||
Monotherapy vs. combination therapy | 3.47 (0.66) | <0.001 |
Parent vs. self | 1.06 (0.53) | 0.048 |
Race | <0.001 | |
Asian vs. white | −0.19 (0.46) | |
Other vs. white | −3.74 (1.01) | |
Country | 0.002 | |
Canada vs. US | 0.31 (0.68) | |
UK vs. US | 2.49 (0.72) | |
Predictors of Specific Concerns - Oral Chelator | ||
Parent vs. self | 2.61 (0.77) | 0.001 |
Age group | 0.005 | |
Young adult vs. child | 1.42 (0.80) | |
Adult vs. child | 2.39 (0.74) | |
Race | <0.001 | |
Asian vs. white | 1.63 (0.49) | |
Other vs. white | 2.94 (1.01) | |
Female vs. male | −1.19 (0.46) | 0.01 |
Predictors of General Overuse | ||
Race | 0.006 | |
Asian vs. white | 0.26 (0.30) | |
Other vs. white | 2.01 (0.62) | |
Country | 0.05 | |
Canada vs. US | 0.90 (0.37) | |
UK vs. US | 0.48 (0.48) | |
Predictors of General Harm | ||
Age group | 0.04 | |
Young adult vs. child | −0.20 (0.40) | |
Adult vs. child | −0.91 (0.37) | |
Race | 0.02 | |
Asian vs. white | 0.19 (0.31) | |
Other vs. white | 1.76 (0.64) | |
Country | 0.007 | |
Canada vs. US | 0.03 (0.39) | |
UK vs. US | 1.64 (0.52) | |
Predictors of General Benefit | ||
Parent vs. self | 0.62 (0.27) | 0.02 |
Race | 0.03 | |
Asian vs. white | 0.08 (0.25) | |
Other vs. white | −1.33 (0.53) | |
Predictors of Sensitive Soma | ||
Number of complications | 0.29 (0.12) | 0.02 |